Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy

• 出版年: Dermatology Reports
• 主要な著者: Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti
• フォーマット: 論文
• 言語: 英語
• 出版事項: PAGEPress Publications 2025-07-01
• 主題: Psoriasis; adalimumab; biosimilars; efficacy; safety
• オンライン･アクセス: https://www.pagepress.org/journals/dr/article/view/10315
• ISSN: 2036-7392; 2036-7406

Adalimumab (ADA), a monoclonal antibody targeting TNF-α, is effective in treating moderate to severe psoriasis. The emergence of biosimilars, such as GP2017 (Hyrimoz®), has raised concerns about their safety and efficacy compared to the originator. This two-year observational study evaluated the effectiveness and safety of GP2017 in 171 patients from Emilia-Romagna, Italy. Patients were divided into two groups: 78 transitioned from the ADA originator, and 93 were biologic-naive. Changes in the Psoriasis Area and Severity Index (PASI) were analyzed. In the switch group, PASI scores remained stable, while the naive group achieved significant improvements (PASI 75: 52% at 3 months, 89% at 6 months). Adverse events leading to discontinuation were rare. The findings confirm that GP2017 is as effective and safe as the ADA originator, supporting its use as a cost-effective alternative in the treatment of psoriasis. Biosimilars play a crucial role in promoting equitable access to biologic therapies.